<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728221</url>
  </required_header>
  <id_info>
    <org_study_id>118328</org_study_id>
    <nct_id>NCT00728221</nct_id>
  </id_info>
  <brief_title>Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation</brief_title>
  <acronym>ESGC</acronym>
  <official_title>Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ginseng has been used for many years in a wide array of anecdotal medicinal properties.
      Animal and limited clinical research points to the vascular effects of Korean Red Ginseng
      (KRG). The present project aims to assess the efficacy of KRG and contribution of its
      factionated components on various indices of vascular function in healthy individuals. Our
      primary objective is to compare the acute effects of KRG and placebo on endothelial function.
      Moreover, our secondary objective is to evaluate the effect of isolated KRG factions on
      arterial stiffness, blood pressure and vasoactive markers. We hypothesize that (1)
      consumption of KRG will cause an improvement in endothelial function in healthy individuals,
      as compared to placebo; (2) consumption of KRG will cause an improvement in arterial
      stiffness and blood pressure in healthy individuals, as compared to placebo; (3) the
      ginsenoside faction of KRG is primarily responsible for the anticipated vascular effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation of the brachial artery</measure>
    <time_frame>Start and finish of each treatment arm</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>Start and finish of each treatment arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitric Oxide and Cyclic GMP</measure>
    <time_frame>Beginning of and 3 hours into clinical visit</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules (3g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole Korean Red Ginseng root (3g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Korean Red Ginseng</intervention_name>
    <description>Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: whole root in capsules (3g)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Kyonggi-do Farm</other_name>
    <other_name>C. A. Meyer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Korean Red Ginseng (Panax ginseng)</intervention_name>
    <description>Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total ginsenoside fraction in capsules</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Kyonggi-do Farm</other_name>
    <other_name>C. A. Meyer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cornstarch</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Korean Red Ginseng (Panax Ginseng)</intervention_name>
    <description>Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total polysaccharide fraction (panaxans) in capsules</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Kyonggi-do Farm</other_name>
    <other_name>C. A. Meyer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: between 18 and 70 years of age

          -  Healthy individuals (absence of major illnesses)

        Exclusion Criteria:

          -  Primary hypertension (defined by the use of antihypertensive agents or a seated
             systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure
             greater than 90mmHg)

          -  Secondary hypertension (defined as SBP greater than 180mmHg and DBP greater than
             110mmHg)

          -  Grade 3 hypertension (defined as SBP greater than 180mmHg and DBP greater than
             110mmHg)

          -  Diabetes

          -  Chronic kidney disease

          -  Liver disease

          -  Estrogen-sensitive cancer

          -  Heavy alcohol use

          -  Bleeding disorders

          -  Planned surgery

          -  Angina

          -  CHF

          -  Coronary revascularization

          -  Peripheral vascular disease

          -  Coronary/cerebrovascular event in the last 6 months

          -  Prescriptions of MAO inhibitors, SSRIs, diuretics, sympathomimetics, herbal therapies,
             medication affecting nitric oxide synthesis, and/or anticoagulent medications within
             the last 6 months

          -  Sensitivity to any of the ingredients in the treatments or placebo

          -  Chronic use of or frequent prescriptions for NSAIDs

          -  Women of childbearing potential must not be pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Vuksan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Jenkins, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital Clinical Nutrition and Risk Factor Modification Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jovanovski E, Peeva V, Sievenpiper JL, Jenkins AL, Desouza L, Rahelic D, Sung MK, Vuksan V. Modulation of endothelial function by Korean red ginseng (Panax ginseng C.A. Meyer) and its components in healthy individuals: a randomized controlled trial. Cardiovasc Ther. 2014 Aug;32(4):163-9. doi: 10.1111/1755-5922.12077.</citation>
    <PMID>24758417</PMID>
  </reference>
  <results_reference>
    <citation>Jovanovski E, Jenkins A, Dias AG, Peeva V, Sievenpiper J, Arnason JT, Rahelic D, Josse RG, Vuksan V. Effects of Korean red ginseng (Panax ginseng C.A. Mayer) and its isolated ginsenosides and polysaccharides on arterial stiffness in healthy individuals. Am J Hypertens. 2010 May;23(5):469-72. doi: 10.1038/ajh.2010.5. Epub 2010 Feb 4.</citation>
    <PMID>20134405</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ginseng</keyword>
  <keyword>Korean Red Ginseng</keyword>
  <keyword>Ginsenoside</keyword>
  <keyword>Flow Mediated Dilation</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

